Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis

Figure 2

Meta-analyses of the hazard ratios for the included studies examining overall survival (a) and progression-free survival (b) for immunotherapy plus chemotherapy vs. chemotherapy alone. ATE: atezolizumab; DUR: durvalumab; IPI: ipilimumab; PLA: placebo. All these treatments were combined with chemotherapy. (a) indicates phased-IPI, and (b) indicates concurrent-IPI.

(a)

(b)